Condition: Human Papillomavirus Associated Carcinomas · Cervical Cancer · Head and Neck Cancers · Sponsor: The Affiliated Hospital of Qingdao University
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
This description comes directly from the study's public registry record.
Hongying Lv · +86 18661805217 · qdlhytiger@163.com
Always discuss trial participation with your own doctor first.
| The affiliated hosptial of qingdao university | Qingdao, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06544720